logo-loader
viewQ BioMed Inc.

Q BioMed CEO sees significant capital funding for next 3 years

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive announced that its technology partner, Mannin Research Inc, has received a $7.5 million grant from the German state of Saxony to fund the development of its glaucoma therapies.

Corin talked about how the two partners plan to accelerate the pre-clinical efforts of its two approaches to prevent glaucoma.

Quick facts: Q BioMed Inc.

Price: 1.7 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $38.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed advancing its liver cancer treatment through the pipeline

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the biotech will advance Uttroside-B in its portfolio and move it quickly towards monetization. Corin says the efficacy of Uttroside-B, a potent saponin, was demonstrated in a preclinical study published in the November 2016 issue of...

2 weeks, 2 days ago

2 min read